PE-22-28

Resumen del Protocolo

Resumen conciso del régimen diario.

• Objetivo:Support rapid neuroplasticity, mood regulation, and neuroprotección through selective TREK-1 inhibition.
• Programa:Inyecciones subcutáneas diarias por 12–16 semanas (8 semanas minimum).
• Rango de dosis:50–200 µg daily with conservative titration; many find 100–150 µg adequate.
• Reconstitución:3.0 mL por vial de 10 mg (~3.33 mg/mL) for precise low-volume measurements.
• Almacenamiento:Lyophilized frozen; reconstituted refrigerated; replace vials cada 4 semanas.

Protocolo de Dosis

Suggested conservative daily titration approach.

• Inicio:50 µg diarias durante Semanas 1–2 para evaluar tolerancia.
• Aumentar:100 µg diarias durante Semanas 3–8 (standard dosis de mantenimiento).
• Optional Titration:150 µg (Semanas 9–12) or 200 µg (Semanas 13–16) only if well-tolerated and additional effect desired.
• Frecuencia:Una vez al día (subcutáneo).
• Duración del ciclo:12–16 semanas; 8 semanas minimum.
• Momento de aplicación:Consistent daily time; rotar sitio de inyeccións systematically.

Pasos para Reconstituir

• Extraer3.0 mLde agua bacteriostática con una jeringa estéril.
• Inyectar lentamente por la pared del vial; evitar que haga espuma.
• Girar suavemente hasta que se disuelva (no agitar).
• Label and refrigerate at2–8 °C (35.6–46.4 °F), protegido de la luz.

Potential Benefits & Observed Safety Profile

Observations de la literatura preclínica and mechanistic studies.

• Rapid Antidepressant Effects:Produces behavioral improvements within 4 días in rodent models; reduces immobility in forced swim tests and decreases latency to feed in novel environments.
• Mejorard Neuroplasticity:Aumentars hippocampal neurogenesis, synaptogenesis markers (PSD-95), dendritic spine density, and BDNF expression within días.
• Neuroprotection:In stroke models, preserves dopaminergic neurons, reduces motor deficits, and prevents post-stroke depressive behavior.
• Favorable Safety Profile:Shows high selectivity with no effects on hERG channels (cardiac safety), no impact on heart rate, blood pressure, glucose regulation, or pain perception in estudios preclínicos. No TREK-1-related side effects or withdrawal observed.
• No Human Data:All evidence is from cell culture and animal studies; human safety and pharmacokinetics remain unestablished.
• Potential Mild Reactions:Subcutaneous administration may occasionally cause minor inyectarion-site reactions (slight redness or tenderness).